USSTOCK.TODAY
Regular Market
Log in Sign up

Ionis Pharmaceuticals beats Q3 revenue but lowers TRYNGOLZA guidance

Barrons.com +3 · ·by G4L

IONS
IONS Ionis Pharmaceuticals Inc
$28.19 -9.06%
View chart & analysis →
  1. 1Ionis Pharmaceuticals recorded Q3 revenue of $243 million.
  2. 2Ionis Pharmaceuticals lowered its 2026 TRYNGOLZA guidance to approximately $50 million.
  3. 3Ionis Pharmaceuticals pushed back its cash flow break-even target from 2028 to 2029.

So what's the key point?

Ionis Pharmaceuticals' Q3 revenue of $243 million was higher than expected. However, the company lowered the future revenue outlook for a specific drug and delayed its timeline to reach profitability.

Source Barrons.com +3 · View original ↗

Related 3-line summaries

Ionis Pharmaceuticals reports $243 million in third-quarter revenue The Motley Fool +1 · yesterdayIonis Pharmaceuticals beats expectations with $243 million in Q3 revenue Associated Press +1 · yesterdayNvidia CEO Jensen Huang Faces Spy Allegations and Leadership Crisis Zero Hedge +20 · 2d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news